Development of an ultra-sensitive human cardiac troponin I sandwich ELISA

Wednesday 29 April 2026
07:00 [PDT]  10:00 [EDT]  15:00 [BST]
Alternative time zones

Discover how Exazym®‘s BOLD amplification technology delivers 180x improved sensitivity for cardiac troponin I detection via standard ELISA.

Detecting ultra-low levels of cardiac troponin I (cTnI) is crucial for cardiac research, yet standard assays often fall short for demanding applications like biomarker studies or drug safety monitoring. In this webinar, Peter Stenlund from Cavidi demonstrates how BOLD (Binding Oligo Ladder Detection) signal amplification achieved a 180-fold sensitivity improvement in a human cTnI sandwich ELISA, lowering the detection limit to 0.07 pg/mL, without specialized equipment or major protocol changes. Discover how to elevate your cardiac biomarker research using existing workflows.

Can’t see the form below? Register for the webinar here.

REGISTER NOWWhat will you learn?Who may this interest?Speaker

What will you learn?

  • Step-by-step mechanics behind BOLD signal amplification, from antibody conjugation to signal generation
  • How to integrate BOLD into existing ELISA protocols with minimal adjustments, including optimizations for capture/detector antibodies and temperature flexibility
  • How Exazym®’s BOLD signal amplification technology works within standard sandwich ELISA workflows to achieve a 180-fold improvement in cardiac troponin I detection sensitivity
  • How the cTnI detection limit was lowered to 0.07 pg/mL, enabling detection of heart injury at its earliest molecular stages
  • Real-world impact of ultra-sensitive cTnI detection: identifying cardiotoxic effects sooner in drug development, unlocking new insights into heart disease progression and improving patient care through earlier risk detection

Who may this interest?

  • Assay developers looking to enhance existing sandwich ELISA sensitivity without investing in new instrumentation
  • Cardiovascular researchers seeking ultra-sensitive detection of cardiac troponin I beyond the reach of conventional ELISA
  • Scientists and lab managers in biomarker discovery, professionals in drug development and CROs requiring improved cTnI sensitivity
  • Researchers in cardiology, drug safety monitoring and precision diagnostics, working with low-abundance cardiac biomarkers
  • Scientists in clinical development and clinical diagnostics needing to detect cardiotoxic effects at lower doses and earlier timepoints

Speaker

Peter Stenlund

Principal Scientist

Cavidi AB

Peter Stenlund is a protein chemist with a PhD in biochemistry from Umeå University (Sweden). His career spans roles as a senior lecturer, postdoctoral scientist in the U.S. and development scientist at Biacore (Uppsala, Sweden), as well as senior scientist positions at Octapharma (Lachen, Switzerland) and Galderma (Lausanne, Switzerland). He brings deep expertise in analytical development for protein drug characterization. As principal scientist at Cavidi AB, Stenlund now leads innovation in ultra-sensitive immunoassay solutions, making him the ideal guide for this technical deep dive into BOLD signal amplification.

 

In association with Cavidi.